Donate | Print Page | Contact Us | Report Abuse | Sign In | Join/Renew
President's Message
Blog Home All Blogs
Search all posts for:   


View all (4) posts »

ASENT Takes Annual Meeting to the Next Level

Posted By Thomas P. Sutula, Thursday, October 31, 2019

Dear Colleagues and Friends:

Welcome to the American Society for Experimental Neurotherapeutics (ASENT) website and we thank you for your interest.  ASENT is an independent, non-profit organization established in 1997 by leaders in academia, government, advocacy and industry to facilitate the processes that bring new therapies to patients with neurological disorders.  


Our major annual activity is a unique, highly interactive annual meeting which brings together a surprising mix of individuals including academic investigators, industry researchers, government regulatory and funding agencies (FDA and NIH), and patient advocates.  These diverse ASENT constituents share a commitment to address the challenges of development of new treatments for neurological diseases.  ASENT seeks to promote interactions across disciplinary perspectives and among the diverse scientific, professional, and patient communities dedicated to development of new therapies for neurological diseases.  With the remarkable progress afforded by contemporary molecular and imaging sciences, digital technologies, and the practical reality of precision medicine for both common and rare diseases, the age of therapeutics for neurological diseases is not only developing, but is rapidly advancing.



Now in its 22nd year, the ASENT Annual Meeting provides a special opportunity for discussion of the challenges of therapy development from perspectives of basic discovery in both academic and industry laboratories, regulatory science, clinical trials, and patient needs.  The range of therapeutic approaches addressed at the meeting includes novel small molecules, drugs in development, biologicals, gene therapy, neurostimulation and device therapy, and wearable technologies for both common and rare diseases of the nervous system.  Through its annual meeting, ASENT seeks to serve scientific, medical, industry, and patient communities as a forum for education and training in translational research.  The informal, highly interactive setting spanning individuals from academia, industry, government, and patient advocacy is unlike any other scientific or professional meeting. 



At the annual meeting in Bethesda, MD, ASENT also hosts the NIH-sponsored course “Training in Neurotherapeutics Discovery and Development for Academic Scientists”. The course covers the principles of drug discovery and development, including identification of lead compounds, discovery of small molecule therapies, biological therapies such as antibodies, antisense oligonucleotides, gene therapies, cell therapies, and IND enabling studies with a focus on the unique challenges inherent in developing treatments for nervous system disorders.  The course is intended for academic neuroscientists who are planning to conduct drug discovery research. 



Beyond the annual meeting, ASENT seeks to advance understanding and promote development of therapeutics for disorders of the nervous system through Neurotherapeutics®, the official journal of the Society.  Neurotherapeutics®  began publication in 2004, and each quarterly issue provides critical reviews focused on a single important topic relating to treatment of neurological disorders, as well as original research articles and current perspectives on hot topics in the field.  Neurotherapeutics® is published by Springer with full-text online access.



Thank you for your interest in ASENT, and we look forward to seeing you in Bethesda, MD on March 2-5, 2020!  


Tom Sutula, MD, PhD
University of Wisconsin, Madison
ASENT President


This post has not been tagged.

Share |
Permalink | Comments (0)
American Society for Experimental Neurotherapeutics
230 Kings Highway East, Ste 245
Haddonfield, NJ 08033
p: 833.273.6800

  Connect with Us: